Form 4: Edwards Lifesciences Officer Executes 10b5-1 Plan

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, executed pre-planned stock option exercises and sales.

Summary

• Donald E. Bobo Jr., CVP, Strategy/Corp Development at Edwards Lifesciences Corp (EW), reported transactions under a Rule 10b5-1 trading plan adopted on February 27, 2025.
• On January 6, 2026, Mr. Bobo exercised employee stock options to acquire 11,340 shares of common stock at an exercise price of $59.2567 per share.
• Concurrently, he sold 2,632 shares of common stock at a weighted average price of $84.6206 per share.
• He also sold an additional 8,708 shares of common stock at a weighted average price of $85.9793 per share.
• Following these transactions, Mr. Bobo directly holds 31,870.2532 shares, indirectly holds 38,817.6991 shares in a 401(k), and 135,152 shares by trust.
• He also beneficially owns 34,020 unexercised employee stock options.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction under a pre-arranged 10b5-1 plan, which typically has a neutral impact on sentiment as it's not indicative of new information.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating these are pre-scheduled trades not based on new, non-public information.

Negatives

• The sales represent a reduction in direct beneficial ownership of common stock by the officer.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Donald E. Bobo Jr., an officer of Edwards Lifesciences, engaged in transactions involving the company's securities, which are considered related party transactions due to his insider status. These transactions were executed under a Rule 10b5-1 trading plan.

Stakeholder Impact

• Shareholders: The sale of shares by an officer, even if pre-planned, slightly increases the float and could be perceived as a lack of confidence, though the 10b5-1 plan mitigates this perception. The exercise of options indicates the officer is realizing value from their compensation package.

Key Dates

Recommendation

The filing is a routine Form 4 detailing insider transactions under a pre-arranged 10b5-1 plan. Such transactions are typically not indicative of new material information and therefore do not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold based on the company's fundamentals and broader market conditions.

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Donald E. Bobo Jr., Corporate Development, Officer Transaction